Sep 2026· European Journal of Haematology· 0 citations· 15 references
Medicine
TL;DR
This study represents the largest reported cohort of patients with TP53-altered LBCL and provides important insights into treatment outcomes across lines of therapy in the era of novel agents.
Abstract
Advances in the treatment of large B-cell lymphoma (LBCL) have expanded therapeutic options beyond conventional chemoimmunotherapy to include cellular and targeted therapies. There is growing interest in identifying subsets of LBCL that may benefit from these novel approaches based on histopathologic and molecular features. Molecular subclassification has identified an LBCL A53 phenotype characterized by TP53 alterations, a subgroup historically associated with poor outcomes following standard therapy. To better define progression-free and overall survival outcomes in TP53-altered LBCL in the contemporary treatment era, we conducted a multicenter cohort study evaluating responses to first-, second-, and third-line therapies. Our findings demonstrate that TP53-altered LBCL can be cured with first-line curative intent chemoimmunotherapy. In the second and third-line setting, outcomes did not significantly differ between different treatment approaches, though improved PFS was seen with CAR-T in the second line for double hit patients. This study represents the largest reported cohort of patients with TP53-altered LBCL and provides important insights into treatment outcomes across lines of therapy in the era of novel agents.
OBJECTIVES
B-cell maturation antigen (BCMA)-targeted therapies have recently transformed the management of relapsed or refractory multiple myeloma (RRMM). This study aimed to evaluate their implementation and real-world impact within EMMY, a French longitudinal cohort.
METHODS
Patients initiating a fourth or later li...
T. Cazaubiel, O. Decaux, A. Perrot et al.· European Journal of Haematol...· 0 citations
Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma responsible for 30–40% of adult non-Hodgkin lymphoma cases. It can develop on its own or from indolent lymphoma.1-2 R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) has been the front-line standard therapy choice since 2002, but a...
Jia Liu, N. Johnson· Canadian Hematology Today· 0 citations
The prognostic impact of the diagnosis-to-treatment interval (DTI) in diffuse large B-cell lymphoma (DLBCL) remains controversial. We investigated the association between DTI and three-year all-cause mortality in a nationwide cohort. We conducted a retrospective population-based cohort study using harmonised German can...
Susanne von Kroge, Nils Janis Steinhaus, Carsten Bokemeyer et al.· BMC Cancer· 0 citations
Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematologic malignancy with a defined, first-line (1L) standard of care (SOC). Several novel agents have been approved for the treatment of relapsed/refractory (R/R) disease in recent years, leading to a heterogeneous treatment landscape in l...
Michael Wallington, Yong Chen, Fei Jie et al.· Journal of Clinical Medicine· 0 citations
Overall survival, CRS, ICANS, and sepsis rates were comparable between extranodal and nodal disease cohorts, and CAR-T therapy as equally effective in extranodal involvement should not influence treatment eligibility decisions.
CD19-directed chimeric antigen receptor T cell therapy (CART) has transformed treatment of relapsed or refractory (r/r) large B cell lymphoma (LBCL); however, organ-specific response patterns and depth of response (DoR) remain insufficiently characterized. This study evaluated organ-specific imaging response and the im...
M. Kassube, P. Achhammer, Philipp Linden et al.· Cancer Immunology and Immuno...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.